IP Library › Granted Patent US 12,746,347
Granted Patent B2
US 12,746,347 · App. 19/031,881 · Granted Sep 29, 2026

Injectable administration compliance platform

Inventor: Jeremy Corbett (Lexington, KY)
Assignee: DataDose, LLC
A61M5/5086A61M5/31566A61M5/427G09B5/04G09B5/065G16H10/60G16H20/17G16H40/63G16H50/20A61M2205/3327A61M2205/3592A61M2205/58A61M2205/581A61M2205/582A61M2205/583
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,746,347
App. No.
19/031,881
Granted
Sep 29, 2026
Kind
B2
Abstract

A method, computer program product, and computer system for an injectable administration compliance platform for real-time monitoring and management of adherence to a program for administration of a set of injectables. The platform may include: a server to receive administration data from a wireless module associated with an intelligent injection device. The administration data may include at least one of: an injection device ID, a drug ID, a patient ID, a potency value, an administration completion flag, a timestamp, or temperature data. A database may store treatment schedules. An artificial intelligence module may: calculate a compliance score, and compare the compliance score to a compliance threshold to categorize the injection event. An alerts module may be included. A monitoring system may track user compliance in substantially real-time. A recommendation system may generate health suggestions. The platform may further include a reporting module, a verification module, and a dashboard.

Claims (90)

1 . An injectable administration compliance platform for real-time monitoring and management of adherence to a program for administration of a set of injectables, the injectable administration compliance platform comprising:

a server configured to receive administration data from a wireless module associated with an intelligent injection device, wherein the administration data includes at least one of: an injection device ID, a drug ID, a patient ID, a potency value, an administration completion flag, a timestamp, or temperature data;

a database configured to store treatment schedules associated with injectable medication administration;

one or more processors and one or more memories comprising:

an artificial intelligence module configured to:

calculate a compliance score for an injection event based on conformance of the administration data to at least one criterion of a treatment schedule of the treatment schedules, and

compare the compliance score to a compliance threshold metric to categorize the injection event as one of compliant, non-compliant or indeterminate;

an alerts module configured to generate and send notifications to a user based on categorization of the injection event;

a monitoring system configured to track user compliance with prescribed medication regimens in substantially real-time;

a recommendation system configured to generate personalized health suggestions based on received patient data;

a reporting module configured to generate adherence reports for healthcare providers;

a verification module configured to ensure proper medication administration by validating user identity;

wherein the verification module is operatively coupled to a locking mechanism, wherein the verification module is further configured to actuate the locking mechanism to transition the intelligent injection device from a locked state that physically prevents injection administration to an unlocked state that physically allows the injection administration responsive to the verification module validating the user identity prior to the injection administration; and

a dashboard configured to provide visual information related to injection administration compliance;

wherein the injectable administration compliance platform is configured to:

receive additional data from at least one of: an IoT device, a wearable device, or an electronic medical record system,

process the additional data in combination with the administration data to make medical determinations, and

automatically determine changes to at least one of: dosage, timing, and attributes of the injection administration based on processing the additional data.

2 . The injectable administration compliance platform of claim 1 , wherein the program is prescribed by a physician and stored in the database.

3 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform receives the administration data collected from the intelligent injection device, wherein the administration data includes at least one of: substance type, substance amount ejected, duration of substance release, temperature of substance, and substance identifier.

4 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform uses the administration data to make medical treatment determinations, wherein the medical treatment determinations include at least one of: adjustments to patient treatment based on the administration data and changes to the dosage or the timing based on the received patient data.

5 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform uses the administration data to make insurance coverage determinations, wherein the insurance coverage determinations include at least one of: increasing or lowering insurance rates and claim payouts based on whether the administration data indicates legitimate or fraudulent injection.

6 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform uses the administration data to make manufacturing determinations, wherein the manufacturing determinations include at least one of: design adjustments, assembly adjustments, and factory adjustments based on the administration data.

7 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform uses the administration data in connection with clinical trials of injectable medications, wherein the injectable administration compliance platform records exact injection timing to ensure accurate reporting and adherence to clinical trial protocols.

8 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform uses the administration data to make a legal and regulatory compliance determination through a compliance/reporting/validation system that ensures regulatory requirements are met.

9 . The injectable administration compliance platform of claim 8 , wherein the legal and regulatory compliance determination is based at least in part on location-specific or jurisdiction-specific constraints or requirements through a privacy/governance system that protects the received patient data according to legal standards in regions with data protection laws.

10 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform is integrated with at least one of an emergency medical record (EMR) system or an emergency health record (EHR) system, wherein integration enables automatic population of one or more fields of the at least one of the EMR system/or the EHR fields with the administration data.

11 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform is integrated with a clinical provider or caregiver portal configured to enable healthcare providers to monitor compliance remotely and make treatment and coverage decisions based on stored treatment data.

12 . The injectable administration compliance platform of claim 1 , wherein the injectable administration compliance platform is integrated with a patient portal configured to enable the user to:

manage the treatment schedules,

view medication history,

manage appointments,

refill prescriptions, and

communicate with healthcare providers.

13 . The injectable administration compliance platform of claim 10 , wherein a set of events from the intelligent injection device are automatically delivered to populate the one or more fields of the at least one of the EMR system or the EHR system, wherein the set of events include the administration data comprising at least one of:

the injection device ID,

the drug ID,

the patient ID,

the potency value,

the administration completion flag,

the timestamp, and

the temperature data.

14 . A platform for managing injectable medication administration, comprising:

a server configured to receive administration data from an intelligent injection device;

a database configured to store treatment schedules;

one or more processors and one or more memories comprising:

an artificial intelligence module configured to:

calculate a compliance score for an injection event based on the administration data and a treatment schedule of the treatment schedules, and

categorize the injection event as compliant or non-compliant;

an alerts module configured to generate notifications based on the categorization of the injection event;

a verification module configured to ensure proper medication administration by validating user identity;

wherein the verification module is operatively coupled to a locking mechanism, wherein the verification module is further configured to actuate the locking mechanism to transition the intelligent injection device from a locked state that physically prevents injection administration to an unlocked state that physically allows the injection administration responsive to the verification module validating the user identity prior to the injection administration; and

a dashboard configured to provide visual information related to injection administration compliance;

wherein the platform is configured to process the administration data to make at least one of:

medical determinations,

insurance coverage determinations, and

manufacturing determinations.

15 . The platform of claim 14 , wherein the artificial intelligence module is further configured to:

learn from a training set of data to optimize scheduling of future injection administration actions,

detect user behaviors that negatively impact wellness or injection programs, and generate alerts to warn the users about the user behaviors.

16 . The platform of claim 14 , wherein the artificial intelligence module is further configured to:

determine whether the intelligent injection device was fraudulently used or wasted based on the administration data, and

trigger alerts or prevention mechanisms if fraudulent use is detected.

17 . The platform of claim 14 , wherein the platform is integrated with at least one of:

an IoT device configured to collect environmental data,

a wearable devices configured to collect patient biometric data, and

an electronic medical record systems configured to store patient treatment data.

18 . The platform of claim 14 , wherein the verification module is further configured to:

validate authenticity of the intelligent injection device, and

prevent medication errors in institutional settings.

19 . The platform of claim 14 , wherein the platform further includes a custody and supply chain management system configured to:

track medications from manufacturer to patient,

ensure the medications are securely managed,

reduce risk of errors and fraud, and

enhance patient safety.

20 . A method for managing administration of injectable medications via an injectable administration compliance platform, comprising:

receiving, by a server, administration data from a wireless module associated with an intelligent injection device, wherein the administration data includes at least one of: an injection device ID, a drug ID, a patient ID, a potency value, an administration completion flag, a timestamp, and temperature data;

storing treatment schedules in a database associated with the injectable administration compliance platform;

calculating, by an artificial intelligence module, a compliance score for an injection event based on conformance of the administration data to at least one criterion of a treatment schedule of the treatment schedules;

comparing the compliance score to a compliance threshold metric to categorize the injection event as one of compliant, non-compliant or indeterminate;

generating and sending, by an alerts module, a message summarizing categorization of the injection event to a party associated with the treatment schedule;

providing a user interface for controlling and configuring the platform;

tracking user compliance with a medication regimen through a monitoring system;

generating personalized health suggestions based on patient data through a recommendation system;

generating detailed reports on patient adherence through a reporting module;

verifying medication is being administered by or to a correct person through a verification module;

actuating a locking mechanism to transition the intelligent injection device from a locked state that prevents injection administration to an unlocked state that allows the injection administration responsive to the verification module verifying the medication is being administered by or to the correct person prior to the injection administration;

displaying visual information related to injection administration compliance through a dashboard;

receiving additional data from at least one of: an IoT device, a wearable device, and an electronic medical record system; and

processing the additional data in combination with the administration data to automatically determine changes to at least one of: dosage, timing, and attributes of injection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2025
From: CORBETT, JEREMY
To: DATADOSE, LLC
Reel/Frame 070290/0193 →
Continuity (3)
Continuation 19031031 · Jan 17, 2025
Provisional Application 63715505 · Nov 1, 2024
Related Publication 20260124402A1 · May 7, 2026
References Cited (171)
US 4950246A · Muller · 1990 [cited by applicant]
US 7300418B2 · Zaleski · 2007 [cited by applicant]
US 9317916B1 · Hanina · 2016 [cited by examiner]
US 9623191B2 · Uber et al. · 2017 [cited by applicant]
US 10825560B1 · Berenson · 2020 [cited by applicant]
US 10911515B2 · Biasi et al. · 2021 [cited by applicant]
US 11102304B1 · Jain et al. · 2021 [cited by applicant]
US 11210611B2 · Kamen et al. · 2021 [cited by applicant]
US 12260959B1 · Minetti et al. · 2025 [cited by applicant]
US 20010047281A1 · Keresman, III et al. · 2001 [cited by applicant]
US 20030036683A1 · Kehr et al. · 2003 [cited by applicant]
US 20030110060A1 · Clementi · 2003 [cited by applicant]
US 20070179453A1 · Lim et al. · 2007 [cited by applicant]
US 20070219503A1 · Loop et al. · 2007 [cited by applicant]
US 20070225653A1 · Lim et al. · 2007 [cited by applicant]
US 20090076338A1 · Zdeblick et al. · 2009 [cited by applicant]
US 20110009812A1 · Brown · 2011 [cited by applicant]
US 20120209243A1 · Yan · 2012 [cited by applicant]
US 20130023813A1 · Roorda · 2013 [cited by applicant]
US 20130023825A1 · Edwards et al. · 2013 [cited by applicant]
US 20130276785A1 · Melker et al. · 2013 [cited by applicant]
US 20130310756A1 · Whalley et al. · 2013 [cited by applicant]
US 20130338628A1 · Robertson et al. · 2013 [cited by applicant]
US 20140074454A1 · Brown et al. · 2014 [cited by applicant]
US 20140180711A1 · Kamen et al. · 2014 [cited by applicant]
US 20140207099A1 · Nagar et al. · 2014 [cited by applicant]
US 20150057611A1 · Bureau · 2015 [cited by applicant]
US 20150112703A1 · Sysko et al. · 2015 [cited by applicant]
US 20150174342A1 · Mitrosky et al. · 2015 [cited by applicant]
US 20150278924A1 · Maurer et al. · 2015 [cited by applicant]
US 20160012205A1 · Saint et al. · 2016 [cited by applicant]
US 20160042154A1 · Goldberg et al. · 2016 [cited by applicant]
US 20160171597A1 · Todeschini · 2016 [cited by applicant]
US 20160171777A1 · Todeschini et al. · 2016 [cited by applicant]
US 20160243318A1 · Despa et al. · 2016 [cited by applicant]
US 20160259913A1 · Yu et al. · 2016 [cited by applicant]
US 20170007765A1 · Cowe et al. · 2017 [cited by applicant]
US 20170076060A1 · Pilkington et al. · 2017 [cited by applicant]
US 20170095638A1 · Young et al. · 2017 [cited by applicant]
US 20170119969A1 · McCullough et al. · 2017 [cited by applicant]
US 20170136185A1 · Rios et al. · 2017 [cited by applicant]
US 20170146381A1 · Eckel et al. · 2017 [cited by applicant]
US 20170203030A1 · Brewer et al. · 2017 [cited by applicant]
US 20170245943A1 · Foster et al. · 2017 [cited by applicant]
US 20170262604A1 · Francois · 2017 [cited by applicant]
US 20170325091A1 · Freeman et al. · 2017 [cited by applicant]
US 20170357775A1 · Ekin · 2017 [cited by applicant]
US 20180017531A1 · Juhnke et al. · 2018 [cited by applicant]
US 20180085517A1 · Laurence et al. · 2018 [cited by applicant]
US 20180113985A1 · Gandy et al. · 2018 [cited by applicant]
US 20180133400A1 · Almoumen · 2018 [cited by applicant]
US 20180166163A1 · Sudharsan · 2018 [cited by applicant]
US 20180182491A1 · Belliveau et al. · 2018 [cited by applicant]
US 20180193564A1 · Dahmani · 2018 [cited by applicant]
US 20180308569A1 · Luellen · 2018 [cited by applicant]
US 20180333543A1 · Diaz et al. · 2018 [cited by applicant]
US 20180369488A1 · Carlsson et al. · 2018 [cited by applicant]
US 20190054247A1 · Dantsker et al. · 2019 [cited by applicant]
US 20190060577A1 · Vallis · 2019 [cited by applicant]
US 20190130792A1 · Rios et al. · 2019 [cited by applicant]
US 20190209777A1 · O'Connell et al. · 2019 [cited by applicant]
US 20190247050A1 · Goldsmith · 2019 [cited by applicant]
US 20190262534A1 · Agard et al. · 2019 [cited by applicant]
US 20190282761A1 · Wilson et al. · 2019 [cited by applicant]
US 20200016331A1 · Lee et al. · 2020 [cited by applicant]
US 20200061301A1 · Hatamian et al. · 2020 [cited by applicant]
US 20200082327A1 · Arefieg · 2020 [cited by applicant]
US 20200086046A1 · Corbett · 2020 [cited by examiner]
US 20200093993A1 · O'Rourke et al. · 2020 [cited by applicant]
US 20200139053A1 · Faught et al. · 2020 [cited by applicant]
US 20200226951A1 · Rios et al. · 2020 [cited by applicant]
US 20200289751A1 · Despa et al. · 2020 [cited by applicant]
US 20200303047A1 · Bostic et al. · 2020 [cited by applicant]
US 20200350052A1 · Saint et al. · 2020 [cited by applicant]
US 20200364801A1 · Basra · 2020 [cited by applicant]
US 20200390596A1 · Chalberg, Jr. et al. · 2020 [cited by applicant]
US 20210008294A1 · Gentz · 2021 [cited by applicant]
US 20210060246A1 · Weydt et al. · 2021 [cited by applicant]
US 20210217516A1 · Nash et al. · 2021 [cited by applicant]
US 20210260289A1 · Kamath et al. · 2021 [cited by applicant]
US 20210288950A1 · Rodriguez Bravo et al. · 2021 [cited by applicant]
US 20220023391A1 · Michelich et al. · 2022 [cited by applicant]
US 20220031956A1 · Helmer · 2022 [cited by applicant]
US 20220051778A1 · Kühni et al. · 2022 [cited by applicant]
US 20220183915A1 · Augustine et al. · 2022 [cited by applicant]
US 20220301681A1 · Coetzee · 2022 [cited by applicant]
US 20220336074A1 · Bakos et al. · 2022 [cited by applicant]
US 20230081577A1 · Walker et al. · 2023 [cited by applicant]
US 20230191036A1 · Corbett · 2023 [cited by examiner]
US 20230298723A1 · Mercolino et al. · 2023 [cited by applicant]
US 20230302224A1 · Prince et al. · 2023 [cited by applicant]
US 20230330328A1 · Moberg et al. · 2023 [cited by applicant]
US 20230368226A1 · Mestres et al. · 2023 [cited by applicant]
US 20230386677A1 · Ferro et al. · 2023 [cited by applicant]
US 20230414432A1 · Augustine et al. · 2023 [cited by applicant]
US 20230414433A1 · Augustine et al. · 2023 [cited by applicant]
US 20240157045A1 · Kostal et al. · 2024 [cited by applicant]
US 20240232031A1 · Kang et al. · 2024 [cited by applicant]
US 20240285956A1 · Forsell · 2024 [cited by applicant]
US 20250000453A1 · Lettman et al. · 2025 [cited by applicant]
US 20250050014A1 · Shin et al. · 2025 [cited by applicant]
US 20250054615A1 · Ronen et al. · 2025 [cited by applicant]
US 20250329451A1 · Minetti et al. · 2025 [cited by applicant]
US 20260079511A1 · Roychoudhury et al. · 2026 [cited by applicant]
CA 3140408A1 · 2020 [cited by applicant]
EP 3991771A1 · 2022 [cited by applicant]
WO 2006060572A1 · 2006 [cited by applicant]
WO 2016210404A1 · 2016 [cited by applicant]
WO 2017156523A1 · 2017 [cited by applicant]
WO 2018009509A2 · 2018 [cited by applicant]
WO 2018106475A1 · 2018 [cited by applicant]
WO 2020236481A1 · 2020 [cited by applicant]
WO WO2021237085A1 · 2021 [cited by examiner]
Mahzabin, Rahnuma et al. “Blockchain associated machine learning and IoT based hypoglycemia detection system with auto-injection feature.” ArXiv abs/2208.02222 (2022): n. pag. (Year: 2022). [cited by examiner]
Restriction Requirement Office Action for U.S. Appl. No. 17/926,157 dated Sep. 24, 2025, 6 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,940 dated Oct. 17, 2025, 21 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/724,177, dated Oct. 29, 2025, 32 pages. [cited by applicant]
Extended European Search Report, Application No. 21808546.2, dated May 23, 2024, 8 pages. [cited by applicant]
Office Action for U.S. Appl. No. 17/724,177, dated Apr. 11, 2024, 11 pages. [cited by applicant]
Office Action for U.S. Appl. No. 17/724,177, dated Oct. 22, 2024, 13 pages. [cited by applicant]
Office Action for U.S. Appl. No. 16/131,749, dated Apr. 1, 2020, 9 pages. [cited by applicant]
Office Action for U.S. Appl. No. 16/131,749, dated Oct. 1, 2020, 11 pages. [cited by applicant]
Office Action for U.S. Appl. No. 16/131,749, dated Mar. 2, 2021, 13 pages. [cited by applicant]
Office Action for U.S. Appl. No. 16/131,749, dated Sep. 16, 2021, 10 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/131,749, dated Jan. 13, 2022, 7 pages. [cited by applicant]
Written Opinion of the International Searching Authority for Application No. PCT/US21/33646, dated Oct. 20, 2021, 10 pages. [cited by applicant]
International Search Report for Application No. PCT/US21/33646, dated Oct. 20, 2021, 4 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/724,177 dated Apr. 21, 2025, 9 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,780 dated May 19, 2025, 6 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,836 dated Apr. 25, 2025, 6 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,836 dated Jul. 18, 2025, 17 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,854 dated May 9, 2025, 6 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,862 dated May 9, 2025, 6 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,940 dated Apr. 11, 2025, 25 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/031,940 dated Jul. 3, 2025, 13 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,780 dated Dec. 29, 2025, 20 pages. [cited by applicant]
Non-Final Office Action or U.S. Appl. No. 19/314,966 dated Dec. 31, 2025, 42 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/315,011 dated Jan. 7, 2026, 39 pages. [cited by applicant]
Examination Report dated Nov. 17, 2025 for European Application No. 21808546.2, 5 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/031,836 dated Nov. 26, 2025, 26 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/280,969 dated Dec. 1, 2025, 38 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/281,013 dated Dec. 11, 2025, 35 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/281,035 dated Dec. 11, 2025, 29 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,854 dated Jul. 28, 2025, 32 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,862 dated Jul. 29, 2025, 43 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,780 dated Aug. 6, 2025, 30 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/314,936 dated Jan. 13, 2026, 30 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/724,177 dated Jan. 13, 2026, 12 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/926,157 dated Jan. 21, 2026, 53 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/315,027 dated Feb. 6, 2026, 37 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,780 dated Feb. 27, 2026, 26 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/280,969 dated Mar. 4, 2026, 38 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/724,177 dated Mar. 10, 2026, 25 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,870 dated Mar. 25, 2026, 52 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/314,864 dated Mar. 27, 2026, 45 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/281,013 dated Mar. 30, 2026, 29 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/281,035 dated Mar. 30, 2026, 32 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,928 dated Apr. 7, 2026, 53 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/315,011 dated Apr. 7, 2026, 15 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,940 dated Apr. 8, 2026, 28 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,780 dated Apr. 9, 2026, 17 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/724,177 dated Apr. 9, 2026, 16 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/314,936 dated Apr. 10, 2026, 15 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,836 dated Apr. 17, 2026, 23 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,911 dated Apr. 20, 2026, 55 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/314,966 dated Apr. 20, 2026, 24 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,890 dated Apr. 21, 2026, 53 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/451,171 dated Apr. 22, 2026, 37 pages. [cited by applicant]
Faisal S, Samoth D, Aslam Y, Patel H, Park S, Baby B, Patel T. Key Features of Smart Medication Adherence Products: Updated Scoping Review. JMIR Aging. Dec. 19, 2023;6:e50990. doi: 10.2196/50990. PMID: 38113067; PMCID: … [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/451,472 mailed May 13, 2026, 48 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2025/053140 mailed Jun. 10, 2026, 39 pages. [cited by applicant]